China approved on Thursday an innovative nuclear medicine imaging agent developed by a research team led by Professor Wang Fan at Peking University. The agent is the world's first radioactive drug ...
Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing information submitted within the application. Prospective comparisons ...
China has approved a domestically developed radioactive imaging drug to help detect whether lung cancer has spread to lymph nodes, marking a step forward for the country's nuclear medicine industry.
Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to ...
Detailed price information for Algernon Health Inc A (AGNPF) from The Globe and Mail including charting and trades.
Detailed price information for Algernon Health Inc A (AGNPF) from The Globe and Mail including charting and trades.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) provides a market update on its commercial and operational ...
Facility upgrades support clinical-grade manufacturing of Bracco’s microbubble-based cell selection and activation technology ...
Figure][1] T heranostics , or radiotheranostics , is a term that describes how the same radiopharmaceutical can be used for ...
Zacks Small Cap Research on MSN
RADX: RAD 101 phase IIb interim analysis
By John Vandermosten, CFA NASDAQ: RADX RAD 101 Phase IIb Second Interim Data Analysis Approximately three months after the first interim readout from the RAD 101 Phase IIb trial, Radiopharm ...
HOUSTON, TX, UNITED STATES, April 7, 2026 /EINPresswire.com/ -- HeartLung AI today welcomed CMS’s establishment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results